Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon E Frey

Showing results (31-40 of 111) with videos related to

Pageof 12
Sort By:
Vaccine|October 18, 2017
A phase I safety and immunogenicity dose escalation trial of plague vaccine, Flagellin/F1/V, in healthy adult volunteers (DMID 08-0066)Sharon E Frey, Kathleen Lottenbach, Irene Graham, et al.
Plos One|January 26, 2013
Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic reviewMarnie L Elizaga, Sandhya Vasan, Mary A Marovich, et al.
Vaccine|July 22, 2014
Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjectsSharon E Frey, Mari Rose Aplasca-De Los Reyes, Humberto Reynales, et al.
The Journal of Infectious Diseases|September 4, 2004
Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccinationJeffrey S Kennedy, Sharon E Frey, Lihan Yan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 10, 2025
Vaccine and Treatment Evaluation Units: A Historical PerspectiveRobert B Belshe, David I Bernstein, Kathryn M Edwards, et al.
The Journal of Infectious Diseases|June 22, 2014
A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adultsJohn J Treanor, Robert L Atmar, Sharon E Frey, et al.
Nature Communications|October 27, 2010
Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virusRafael A Medina, Balaji Manicassamy, Silke Stertz, et al.
Open Forum Infectious Diseases|April 11, 2019
Safety and Immunogenicity of MF59-Adjuvanted Cell Culture-Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the ElderlySharon E Frey, Sepehr Shakib, Pornthep Chanthavanich, et al.
The Journal of Infectious Diseases|June 16, 2007
The immunogenetics of smallpox vaccinationSamuel L Stanley, Sharon E Frey, Patricia Taillon-Miller, et al.
Transfusion|August 5, 2020
Rapid establishment of a COVID-19 convalescent plasma program in a regional health care delivery networkDouglas Blackall, Shephali Wulff, Timothy Roettger, et al.
Pageof 12

Showing results (31-40 of 111) with videos related to

Sort By:
Pageof 12
Vaccine|October 18, 2017
A phase I safety and immunogenicity dose escalation trial of plague vaccine, Flagellin/F1/V, in healthy adult volunteers (DMID 08-0066)Sharon E Frey, Kathleen Lottenbach, Irene Graham, et al.
Plos One|January 26, 2013
Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic reviewMarnie L Elizaga, Sandhya Vasan, Mary A Marovich, et al.
Vaccine|July 22, 2014
Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjectsSharon E Frey, Mari Rose Aplasca-De Los Reyes, Humberto Reynales, et al.
The Journal of Infectious Diseases|September 4, 2004
Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccinationJeffrey S Kennedy, Sharon E Frey, Lihan Yan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 10, 2025
Vaccine and Treatment Evaluation Units: A Historical PerspectiveRobert B Belshe, David I Bernstein, Kathryn M Edwards, et al.
The Journal of Infectious Diseases|June 22, 2014
A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adultsJohn J Treanor, Robert L Atmar, Sharon E Frey, et al.
Nature Communications|October 27, 2010
Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virusRafael A Medina, Balaji Manicassamy, Silke Stertz, et al.
Open Forum Infectious Diseases|April 11, 2019
Safety and Immunogenicity of MF59-Adjuvanted Cell Culture-Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the ElderlySharon E Frey, Sepehr Shakib, Pornthep Chanthavanich, et al.
The Journal of Infectious Diseases|June 16, 2007
The immunogenetics of smallpox vaccinationSamuel L Stanley, Sharon E Frey, Patricia Taillon-Miller, et al.
Transfusion|August 5, 2020
Rapid establishment of a COVID-19 convalescent plasma program in a regional health care delivery networkDouglas Blackall, Shephali Wulff, Timothy Roettger, et al.
Pageof 12